Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [41] Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
    Bokemeyer, C
    Beyer, J
    Metzner, B
    Ruther, U
    Harstrick, A
    Weissbach, L
    Kohrmann, U
    Verbeek, W
    Schmoll, HJ
    ANNALS OF ONCOLOGY, 1996, 7 (01) : 31 - 34
  • [42] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Ashkar, Ryan
    Feldman, Darren R.
    Adra, Nabil
    Zaid, Mohammad Abu
    Funt, Samuel A.
    Althouse, Sandra K.
    Perkins, Susan M.
    Snow, Christin I.
    Lazzara, Kayla M.
    Sego, Lina M.
    Quinn, David I.
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    Albany, Costantine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1656 - 1663
  • [43] Phase II Clinical Trial of Oxaliplatin and Bevacizumab in Refractory Germ Cell Tumors
    Jain, Amit
    Brames, Mary J.
    Vaughn, David J.
    Einhorn, Lawrence H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05): : 450 - 453
  • [44] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Ryan Ashkar
    Darren R. Feldman
    Nabil Adra
    Mohammad Abu Zaid
    Samuel A. Funt
    Sandra K. Althouse
    Susan M. Perkins
    Christin I. Snow
    Kayla M. Lazzara
    Lina M. Sego
    David I. Quinn
    Nasser H. Hanna
    Lawrence H. Einhorn
    Costantine Albany
    Investigational New Drugs, 2021, 39 : 1656 - 1663
  • [45] PRELIMINARY-RESULTS OF A PHASE I/II TRIAL OF PACLITAXEL IN PATIENTS WITH RELAPSED OR CISPLATIN-REFRACTORY TESTICULAR CANCER
    BOKEMEYER, C
    SCHMOLL, HJ
    NATT, F
    KNOCHE, M
    BEYER, J
    SOUCHON, R
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, 120 (12) : 754 - 757
  • [46] Phase II study of disulfiram (D) and cisplatin (P) in refractory germ cell tumors (GCTs).
    Mego, Michal
    Svetlovska, Daniela
    Schmidtova, Silvia
    Kalavska, Katarina
    Obertova, Jana
    Palacka, Patrik
    De Angelis, Valentina
    Lesko, Peter
    Orszaghova, Zuzana
    Rejlekova, Katarina
    Reckova, Maria
    Sycova-Mila, Zuzana
    Mardiak, Jozef
    Chovanec, Michal
    Kucerova, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17013 - E17013
  • [47] Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors
    Bedano, Pablo M.
    Brames, Mary J.
    Williams, Stephen D.
    Juliar, Beth E.
    Einhorn, Lawrence H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5403 - 5407
  • [48] Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).
    Adra, Nabil
    Althouse, Sandra K.
    Ammakkanavar, Natraj Reddy
    Radovich, Milan
    Albany, Costantine
    Vaughn, David J.
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients
    P. Soulié
    C. Garrino
    M. A. Bensmaïne
    M. Bekradda
    E. Brain
    M. Di Palma
    A. Goupil
    J. L. Misset
    E. Cvitkovic
    Journal of Cancer Research and Clinical Oncology, 1999, 125 : 707 - 711
  • [50] Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients
    Soulié, P
    Garrino, C
    Bensamaïne, MA
    Bekradda, M
    Brain, E
    Di Palma, M
    Goupil, A
    Misset, JL
    Cvitkovic, E
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (12) : 707 - 711
12345